A GLP-1 clinic lives or dies on transparency. Patients have learned the hard way that some clinics quote a teaser monthly rate and add lab fees, consult fees, and shipping at checkout. SleekAI is configured to do the opposite. It quotes the all-in monthly cost for compounded semaglutide, compounded tirzepatide, and any brand pathway you support, names whether labs and consults are included, and tells the patient honestly when a brand is on FDA shortage status and what that means for your compounded program.

The bot reads your published pathway pages from wp_posts and the pricing and inclusion fields from wp_postmeta. It compares your $299 compounded semaglutide all-in track to your $399 compounded tirzepatide track and to your brand-with-insurance pathway with the program-only cost of $199 a month. It explains what your 503A or 503B pharmacy partnership looks like in plain language, notes which states each pathway is available in, and links to the prescriber's schedule on Jane App, SimplePractice, or your custom scheduler.

What it refuses to do is recommend a dose, advise on titration speed, manage side effects in real time, or compare your compounded products to brand on efficacy. Those are prescriber and pharmacist conversations. The bot routes urgent symptoms to your on-call clinical line and surfaces 911 language for chest pain, severe abdominal pain, or signs of pancreatitis. Conversations log with model, tokens, and origin page so the medical director audits each month.

The GLP-1 category is a transparency problem disguised as a marketing problem. Patients have seen the teaser pricing, the asterisk on consult fees, the surprise lab bill, and the compounded pharmacy that vanished when shortage status changed. They arrive on a new clinic site already braced for a bait and switch, which is why honest all-in pricing and clear regulatory language outperform aggressive marketing copy in this niche.

SleekAI fits that posture by default. It quotes the same number for the cash pathway, the insurance pathway, and the compounded tirzepatide alternative every time. It explains the 503A or 503B partnership the way your website explains it.

It names the FDA shortage status in the same words your prescriber would use in the consult. And it refuses every individual dose, titration, and side-effect question with a consistent script that routes to the prescriber visit. Operationally, GLP-1 inquiries cluster heavily in evenings, lunch breaks, and weekend mornings, which is exactly when a small front desk is offline and a per-message SaaS bot starts to feel expensive.

A flat-cost plugin on your own API key turns that pattern into a non-event. The medical director gets a full conversation log every month, the prescriber gets a steadier stream of qualified consults, and patients stop calling to verify a price they should have been able to read in chat the first time.